NCT03874819 (EXPAND) is a NA clinical trial of Medium cut-off dialyzer in Hemodialysis Complication, sponsored by Carlo Maria Guastoni.

Who is sponsoring NCT03874819?

NCT03874819 is sponsored by Carlo Maria Guastoni.

What drugs are being tested in NCT03874819?

Interventions in NCT03874819: Medium cut-off dialyzer, High-flux dialyzer.

What condition does NCT03874819 study?

NCT03874819 studies Hemodialysis Complication.

Is NCT03874819 still recruiting?

NCT03874819 is currently status unknown. Last updated 8 July 2019.

Last reviewed 2019-07-08 · How we verify

NCT03874819: EXPAND

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of a Medium Cut-Off Dialyzer - Medical Device on ESA Resistance in 110 Hemodialysis Patients (EXPAND)

Status unknown NA Last updated 8 July 2019

What this trial tests

NA trial testing Medium cut-off dialyzer in Hemodialysis Complication in 110 participants. Status unknown.

Timeline

15 July 2019

Primary endpoint
15 March 2020

15 March 2020

Quick facts

Lead sponsor	Carlo Maria Guastoni
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	110
Start date	15 July 2019
Primary completion	15 March 2020
Estimated completion	15 March 2020

Drugs / interventions tested

Medium cut-off dialyzer
High-flux dialyzer

Conditions studied

Hemodialysis Complication — all drugs for Hemodialysis Complication →

Sponsor

Carlo Maria Guastoni

Who can join

18 and older, any sex, with Hemodialysis Complication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is hypothesized that a consistent use of Medium cut-off membrane (Theranova) increased clearance of pro-inflammatory molecules in a broad molecular weight range attenuates the chronic inflammatory state in patients with poor response to ESA therapy and absence of absolute iron deficiency and that this leads to an improvement in ESA responsiveness (EPO resistance index).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hemodialysis Complication

Currently open trials in the same condition.

NCT07386691 — Comparing Effect of Intradialytic Aerobic Exercise Versus Incentive Spirometer on Fatigue and Sleep Quality Among Hemodi · NA · active not recruiting
NCT07512895 — The Effect of Progressive Muscle Relaxation Exercises on Depression and Fatigue in Patients Receiving Hemodialysis Treat · NA · recruiting
NCT07047547 — A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure · NA · recruiting
NCT06452563 — Amino Acids Supplementation and Exercise Intervention in Hemodialysis Patients · Phase 4 · active not recruiting
NCT06520631 — Response Of Arteriovenous Fistula Puncture-related Pain To Cryotherapy Application In Haemodialysis Patients · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03874819 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Carlo Maria Guastoni
Last refreshed: 8 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03874819.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing